Management Of Metabolic Syndrome Research Articles

Interactions of Non-Nutritive Artificial Sweeteners with the Microbiome in Metabolic Syndrome.

Replacing sugar with non-nutritive artificial sweeteners (NAS) is a popular dietary choice for the prevention and management of metabolic syndrome and its comorbidities. However, evidence in human trials is conflicted regarding the efficacy of this strategy and whether NAS may counterintuitively promote, rather than prevent, metabolic derangements. The heterogeneity in outcomes may stem in part from microbiome variation between human participants and across research animal vivaria, leading to differential interactions of NAS with gut bacteria. An increasing body of evidence indicates that NAS can alter the mammalian gut microbiome composition, function, and metabolome, which can, in turn, influence host metabolic health. While there is evidence for microbiome-mediated metabolic shifts in response to NAS, the mechanisms by which NAS affect the gut microbiome, and how the microbiome subsequently affects host metabolic processes, remain unclear. In this viewpoint, we discuss data from human and animal trials and provide an overview of the current evidence for NAS-mediated microbial and metabolomic changes. We also review potential mechanisms through which NAS may influence the microbiome and delineate the next steps required to inform public health policies.

Effectiveness of yoga practice on the glycemic status and body mass index in pre-diabetic individuals

Background: Yoga is a healthy lifestyle intervention practice that has claimed beneficial effect in the management of several metabolic syndromes including diabetes mellitus. It has favorable effect on maintaining blood pressure and insulin resistance in pre-diabetic individual. Aim and Objectives: The aim of the study was to assess the effect of yoga practice on the blood glucose levels and body mass index (BMI) in pre-diabetic individuals. Materials and Methods: Cases attending outpatient department of between age group 21–55 years under pre-diabetic category (n = 128) based on laboratory investigations and BMI were recruited. Participants were divided in to two groups, that is, group 1 (Pre-diabetics with yoga practice) and Group 2 (Pre-diabetics without yoga practice). Participants of Group 1 were advised to attend the yoga sessions for 180 days and blood glucose levels and BMI was assessed. Results: In Group 1, the mean blood glucose level was gradually decreased from the beginning (121.57 mg/dl in Group 1 and 121.98 mg/dl in Group 2) to end of 180 days (89.32 mg/dl in Group 1% 105.65 mg/dl in Group 2). The mean BMI was significantly decreased from the beginning (27.63 in Group 1 and 27.24 in Group 2) to the end of 180 days (21.33 in Group 1 and 24.26 in Group 2) in both study groups. The mean difference of glucose levels and BMI among both study groups was statistically significant (P < 0.05). Conclusion: Yoga practice was significantly reduced the BMI and blood glucose in pre-diabetic participants. However, the rate of decline in the levels of blood glucose and BMI was high in pre-diabetics under yoga practice. Continuous yoga adherence and healthy lifestyle practices can improve.

A Review of the Antidiabetic, Antihyperlipidemic, and Related Metabolic Disorder Documented Activities of Emblic Fruits (Phyllanthus emblica L.)

Diabetes is a risky metabolic chronic sickness that threatens the lives and health of individuals, families, and communities everywhere. Management of diabetes and related metabolic syndrome (MS) relies heavily on diet. There are reports of folk plants showing varying levels of antihyperglycemic activity. Phyllanthus emblica Linn (syn. Emblica officinalis) (often referred to Emblic, Indian gooseberry, or amla) is a perennial tree in the Euphorbiaceae family. Due to the high concentration of phenolic compounds, Emblic fruit may be considered a plant source of natural antioxidants. Numerous studies have demonstrated Emblic fruit’s benefits on humans and animals that are antihyperglycemic, anti-inflammatory, antihyperlipidemic, antibacterial, analgesic and antipyretic, adaptogenic, hepatoprotective, anticancer, antiulcerogenic, and antioxidant. This review provided an overview of the published scientific studies (experimental and clinical) that documented the potential antidiabetic and antihyperlipidemic benefits associated with consuming Emblic fruits. In addition, the possible activity regarding related metabolic syndrome and diabetes complications was assessed.

Evaluation of Glycemic Index of Some Cameroonian Local Meals: A Contribution to the Management of Metabolic Syndrome

Evaluation of Glycemic Index of Some Cameroonian Local Meals: A Contribution to the Management of Metabolic Syndrome

Helichrysum italicum (Roth) G. Don and Helichrysum arenarium (L.) Moench infusions in reversing the traits of metabolic syndrome: a double-blind randomized comparative trial.

Health impairments characteristic for metabolic syndrome such as increased body mass, a dysregulated lipid or glucose profile and elevated blood pressure can be reversed by appropriate lifestyle modifications. Supplementing the normal diet with herbal infusions is a promising strategy. We conducted a randomised double-blind comparative study in which participants with at least two traits of metabolic syndrome consumed an infusion of either Helichrysum italicum subsp. italicum (HI, n = 14) or Helichrysum arenarium (HA, n = 13) daily for 28 days. Anthropometric and biochemical parameters were measured at baseline, at the end of the intervention and after a 2-week washout period. HI infusion consumption had a beneficial effect on anthropometric traits; significant reductions in body weight, body mass index, and visceral and total body fat were observed. In the HA group, there was a greater reduction in serum glucose levels and an improvement in the lipid profile. In both groups, high LDL levels were measured at baseline, but two weeks after the intervention, in 84% of participants in the HA group and 71% in the HI group, the levels were within the reference range. Both interventions caused a decrease in HDL but also improved serum antioxidant properties. Consuming either infusion could thus be recommended as a simple, profitable habit for individuals with traits of metabolic syndrome.

The Role of Bioactive Compounds from Dietary Spices in the Management of Metabolic Syndrome: An Overview.

Metabolic syndrome (MetS) is a combination of physiologically dysregulated parameters that can include elevated fasting blood glucose, high blood pressure, central obesity, increased triglyceride levels, insulin resistance, diabetes, elevated low density lipoprotein levels, and reduced high density lipoprotein levels in the blood. Effective clinical management of MetS is critical as it is strongly associated with long lasting and fatal complications in patients. Alongside standard care of lifestyle changes and medication, dietary supplements derived from herbal resources could be an alternative therapeutic strategy that is safe, efficient, culturally acceptable, and has few side effects. Of the dietary supplements, spicy foods have always been considered a great source of functional bioactive compounds. Herbal therapy is broadly used in many countries as a treatment or as a preventive measure in the management of MetS risk factors, including blood glucose, blood pressure, and blood lipid levels. Herein, an attempt is made to evaluate the recent studies in the management of MetS with herbal alternatives, and to explore the possibility of their use as therapeutic treatments or supplements.

Multipotent Stromal Cells from Subcutaneous Adipose Tissue of Normal Weight and Obese Subjects: Modulation of Their Adipogenic Differentiation by Adenosine A1 Receptor Ligands.

Adenosine A1 receptor (A1R) activation, stimulating lipogenesis and decreasing insulin resistance, could be useful for metabolic syndrome management in obese subjects. Since full A1R agonists induce harmful side-effects, while partial agonists show a better pharmacological profile, we investigated the influence of two derivatives of the full A1R agonist 2-chloro-N6-cyclopentyladenosine (CCPA), C1 and C2 behaving as A1R partial agonists in animal models, on the adipogenic differentiation of stromal/stem cells (ASCs) from human subcutaneous adipose tissue, which mainly contribute to increase fat mass in obesity. The ASCs from normal-weight subjects showed increased proliferation and A1R expression but reduced adipogenic differentiation compared to obese individual-derived ASCs. Cell exposure to CCPA, C1, C2 or DPCPX, an A1R antagonist, did not affect ASC proliferation, while mainly C2 and DPCPX significantly decreased adipogenic differentiation of both ASC types, reducing the activity of glycerol-3-phosphate dehydrogenase and the expression of PPARγ and FABP-4, all adipogenic markers, and phosphorylation of Akt in the phosphatidylinositol-3-kinase pathway, which plays a key-role in adipogenesis. While requiring confirmation in in vivo models, our results suggest that A1R partial agonists or antagonists, by limiting ASC differentiation into adipocytes and, thereby, fat mass expansion, could favor development/worsening of metabolic syndrome in obese subjects without a dietary control.

Macronutrient Intake in Adults Diagnosed with Metabolic Syndrome: Using the Health Examinee (HEXA) Cohort.

Macronutrient intake is important in the prevention and management of metabolic syndrome (MetS). This study aimed to evaluate total energy and macronutrient intake of participants diagnosed with MetS at recruitment of the health examinees (HEXA) cohort, considering the plant and animal sources of each macronutrient. We included 130,423 participants aged 40–69 years for analysis. Odds ratios (OR) and 95% confidence intervals (CI) were estimated to evaluate the intake of macronutrients stratified by gender. Energy and macronutrient intake were estimated by linking food frequency questionnaire data to the Korean food composition database, and were calculated separately for plant and animal foods. Low energy (men: OR = 0.95, 95% CI: 0.92–0.98; women: OR = 0.97, 95% CI: 0.95–0.99), and fat intake (men: OR = 0.93, 95% CI: 0.90–0.96; women: OR = 0.80, 95% CI: 0.77–0.83) were observed. Only postmenopausal women had lower intake of total energy (OR = 0.95, 95% CI: 0.92–0.97), whereas low fat intake was observed in all women (OR = 0.80, 95% CI: 0.77–0.83). For carbohydrate intake, the OR were 1.14 (95% CI: 1.08–1.22) and 1.17 (95% CI: 1.08–1.27) among women in their 50s and 60s, respectively. Protein intake was low (OR = 0.90, 95% CI: 0.86–0.95; and OR = 0.88, 95% CI: 0.82–0.94) among women in their 50s and 60s, respectively. High intake of plant carbohydrates in women (OR = 1.16, 95% CI: 1.12–1.20), and plant protein in both genders (OR = 1.09, 95% CI: 1.05–1.13) were observed, but low intake of total energy, fat, and animal-source carbohydrates in both genders was also observed. Fat intake was low regardless of food source. In conclusion, high consumption of plant-source macronutrients, and low consumption of animal-source macronutrients was observed in Korean adults diagnosed with MetS. Attention should be directed to plant sources of carbohydrates and proteins when designing population interventions for metabolic syndrome reduction in Korea.

Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight

Metabolic syndrome is a collection of abnormalities including insulin resistance, hypertension, dyslipidemia, type 2 diabetes, obesity, inflammation, non-alcoholic fatty liver disease, etc. The metabolic syndrome results in a dramatic five-fold elevation in the risk of developing type-2 diabetes and a two-fold heightened risk of developing cardiovascular diseases. It is fast becoming a major global health challenge, cause of mortality and morbidity. Regardless of advances in understanding the mechanisms involved in the pathogenesis of metabolic syndrome, available therapies are still not effective. Nanotechnology is marked as an upcoming tool with a wide range of applications in biomedicine, especially for the management of metabolic syndrome and its associated disorders such as diabetes, obesity, etc. because the nanotechnology utilizes nanoscaled drugs and therapeutics that can reach specific target sites, which helps in improving drug delivery systems, early disease detection and diagnosis using nano-imaging techniques. Therefore, nanotechnology increases bioavailability, permeability, compatibility, the effectiveness of treatment and reduced adverse effects. In this review, we will describe the role of nanomaterial-based therapeutics in managing metabolic disorders such as non-alcoholic fatty liver disease, obesity, insulin resistance, glucose intolerance which all increase the risk of developing cardiovascular diseases and diabetes.

Effect of Beilschmedia obscura on the prevention of high fat/high sucrose diet induced metabolic syndrome on male Albino Wistar rats

IntroductionBeilschmiedia (Lauraceae) is a pantropical genus of about 287 species, distributed in tropical Asia and Africa used in traditional medicines to cure many diseases. This study aimed to explore biological properties of Beilschmiedia obscura (B. obscura) on the prevention and management of metabolic syndrome (MetS) features induced by High Fat/High Sucrose (HF/HS) diet in rats as therapeutic option. MethodsMetS was induced after administration of HF/HS diet followed by administration of B. Obscura powder at 5% or 10% for 21 days, while the control group received a chow diet and distilled water and the positive control group received the HF/HS diet and distilled water. At the end of the experiment, rats were sacrificed; the parameters of lipid profile, markers of oxidative stress, antioxidant status were evaluated. ResultsHF/HS diet successfully induced weight gain, oxidative stress and lipid profile disorders from rats. Treatment with powder of B. obscura at 10% than the 5% showed a reduction of body weight in treated groups and, anti-hyperlipidemic effect by improving lipid profile parameters. Triglycerides, Total cholesterol and LDL cholesterol levels were lower (p<0.05) and HDL-cholesterol levels higher in the treated groups compared to positive control. Inhibition of lipid peroxidation, and improvement protein thiols levels and catalase activity were also observed in treated groups. ConclusionThis study revealed that B. obscura whole plant was efficient in reducing biomarkers involved in metabolic syndrome and could efficiently help in its management by preventive effect.

Role of Sumac (Rhus coriaria L.) in the management of metabolic syndrome and related disorders: Focus on NAFLD-atherosclerosis interplay

Sumac (Rhus coriaria L.) is a commonly used spice in the Mediterranean region and considered as healthy food ingredients. The beneficial value of sumac is well documented in folk medicine. Accumulating data explored the phytochemical, nutritional and therapeutic proprieties suggesting sumac as a potential functional food. Here, we discuss the general and scientific aspects of sumac. Sumac is rich in different polyphenolic compounds such as flavonoids, tannins, and phenolic acids. The potential therapeutic effects of sumac have been studied in various cellular and animal models, as well as in human. These reports suggest that Sumac has potential effect against oxidative stress, inflammation, obesity, hyperglycemia, hypercholesterolemia, and hyperlipidemia, which represent key pathogenic mechanisms contributing to cardio-metabolic, liver, and cancer diseases. Clinical studies using sumac or its major compounds, suggest that this herbal product may represent a useful therapeutic tool in the management of metabolic-related conditions such as liver-atherosclerosis complications.

Effect of Triphala Kajjali tablet - an Ayurvedic herbomineral formulation for the management of metabolic syndrome: a single case study

Metabolic syndrome (MS) is a group of disorders that includes abdominal obesity, diabetes, hypertension, and elevated cholesterol. Approximately 25% of the adult populations are affected by MS. Gradually this number is increasing because of poor lifestyles, faulty dietary pattern, physical inactivity, stressful life and rapid urbanization. A 50-year-old female patient visited to OPD of Kayachikitsa department ITRA, Jamnagar, with the complaints of gradual weight gain with excess body fat around the abdomen and waist region, numbness and burning sensation at bilateral feet, and breathlessness on exertion. After investigation, she was diagnosed as a case of MS as per National Cholesterol Education Program (NCEP), adult treatment panel III (revised in 2005) guideline. She was treated with Triphala Kajjali tablet for 12 weeks along with lifestyle modification. After completion of treatment, investigations revealed reduction in fasting blood sugar from 113 mg/dL to 80 mg/dL, serum cholesterol level was decreased to 148 mg/dl from 216 mg/dl, serum triglycerides level was reduced to 150 mg/dL from 187 mg/dL and serum LDL was reduced to 68.3 mg/dl from 118.7 mg/dl. Her weight reduced to75 kg from 85 kg, and waist circumference reduced to 92 cm from 100cm, and blood pressures also reduced up to 122/82 mmHg from 140/90 mmHg. Hence, it can be concluded that Triphala Kajjali tablet along with lifestyle modification are effective in the management of MS, as it possesses Kapha Medohara properties.

Current Status and Future Perspectives on Therapeutic Potential of Apigenin: Focus on Metabolic-Syndrome-Dependent Organ Dysfunction.

Metabolic syndrome and its associated disorders such as obesity, insulin resistance, atherosclerosis and type 2 diabetes mellitus are globally prevalent. Different molecules showing therapeutic potential are currently available for the management of metabolic syndrome, although their efficacy has often been compromised by their poor bioavailability and side effects. Studies have been carried out on medicinal plant extracts for the treatment and prevention of metabolic syndrome. In this regard, isolated pure compounds have shown promising efficacy for the management of metabolic syndrome, both in preclinical and clinical settings. Apigenin, a natural bioactive flavonoid widely present in medicinal plants, functional foods, vegetables and fruits, exerts protective effects in models of neurological disorders and cardiovascular diseases and most of these effects are attributed to its antioxidant action. Various preclinical and clinical studies carried out so far show a protective effect of apigenin against metabolic syndrome. Herein, we provide a comprehensive review on both in vitro and in vivo evidence related to the promising antioxidant role of apigenin in cardioprotection, neuroprotection and renoprotection, and to its beneficial action in metabolic-syndrome-dependent organ dysfunction. We also provide evidence on the potential of apigenin in the prevention and/or treatment of metabolic syndrome, analysing the potential and limitation of its therapeutic use.

Role of Virechana Karma, Vidangadi Churna and lifestyle modification in Metabolic syndrome (Medoroga): A Case Study

Metabolic syndrome is a group of co-morbidities which pose as a risk factor for cardiovascular disease. It comprises of hypertension, central obesity, impaired glucose metabolism and dyslipidemia. It can be considered under broad umbrella of Santarpaka Nimittaja Vyadhi and can be managed using Chikitsa Sutra for Santarpanottha Vyadhi. In present case study, Virechana was performed to a diagnosed patient of metabolic syndrome, followed with oral medication Vidangadi Churna for 30 days (total duration 45 days). Strict dietary and lifestyle modification including regular physical activity were also suggested to the patient during this period. Patient was assessed on certain symptoms like Kshudra Shwasa, Trisha, Atinidra, etc. together with NCEP ATP III criteria, 2001 before initiation and after the treatment. Symptoms related to Medodushti relieved and also body weight (93 to 81 kg), BMI - 25.3- 24.89, FBS- 118.90 - 103.80, Triglycerides- 239.5-105.3, Total Cholesterol-217.2-191.6 mg/dl, LDL-127.3-112.7 mg/dl, VLDL- 47.9-21.1 mg/dl, HDL- 42.0- 57.8, Average blood pressure - 150/ 100 to 130/ 90 mm. of Hg decreased after treatment. Virechana and Vidangadi Churna accompanied by lifestyle modification are effective in the management of metabolic syndrome.

Public Statement on the Importance of Prevention and Management of Obesity and Metabolic Syndrome during the COVID-19 Pandemic.

Public Statement on the Importance of Prevention and Management of Obesity and Metabolic Syndrome during the COVID-19 Pandemic.

Systematic Review: Vulnerability of Metabolic Syndrome in COVID-19

SARS-CoV-2 infection has become a widely spread disease around the world causing rapid hospitalization and death, especially in people with metabolic syndrome. There is very limited literature that goes to present the clinical implications and management of metabolic syndrome in this pandemic. Hence an attempt has been made towards meeting this end. A literature review has been done extracting articles from scopus database following PRISMA guidelines. The manuscripts were studied to identify articles that report metabolic syndrome and its components in COVID-19 infection. A total of 25 manuscripts were included in this systematic review. These studies report systematic inflammation and organ damage in metabolic syndrome that has up regulated SARS-CoV-2 infection. Various treatment strategies have also been suggested and hypothesized. The results of this analysis indicate that patients suffering from metabolic syndrome are vulnerable to COVID-19 owing a sequence of complications.

Combined Effects of Metabolic Abnormalities and Obesity on Cardiovascular Diseases among Korean Postmenopausal Women.

Combined effects of metabolic abnormalities, including metabolic syndrome and obesity, should be identified to screen postmenopausal women at risk of developing cardiovascular diseases. The purpose of this study was to identify the combined effects of metabolic abnormalities and obesity on cardiovascular diseases among postmenopausal Korean women (aged 40–83 years). Data of 5959 postmenopausal women from the Korean National Health and Nutrition Examination Survey (2015–2018) were secondarily analyzed. Using complex simple analysis procedures, logistic regression analysis was performed to identify the combined effect of metabolic abnormalities and obesity on cardiovascular diseases among postmenopausal Korean women. In combination, metabolic syndrome (more than three metabolic abnormalities) and obesity (overweight [≥23 kg/m2 and <25 kg/m2 in body mass index] and obese [>25 kg/m2 in body mass index]) increased the likelihood of developing cardiovascular diseases but combining more than one metabolic abnormality and obesity did not. Combining metabolic syndrome and non-obesity (underweight and normal weight) increased the likelihood of the prevalence of cardiovascular diseases but combining more than one metabolic abnormality and non-obesity did not. Increased cardiovascular diseases in postmenopausal women may be more commonly associated with metabolic syndrome having multiple metabolic abnormalities, but not obesity. Thus, instead of simple weight control, early management of metabolic syndrome is recommended to prevent cardiovascular disease among postmenopausal Korean women.

Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive Review

Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive Review

Performance of Two Novel Obesity Indicators for the Management of Metabolic Syndrome in Young Adults.

BackgroundMetabolic syndrome (MetS) is a pathophysiological change based on the abnormal metabolism of many substances. The study aims to investigate the performance of visceral adiposity index (VAI) and lipid accumulation product (LAP) of MetS in young adults.Methods448 young adults aged between 19 and 24 years old in Qinhuangdao had been included in this cross-sectional study. Receiver operating characteristic (ROC) curve analyses were used to assess the accuracy of these two obesity indicators for MetS.ResultsThe prevalence of MetS was 2.0%. In male subjects, LAP had the highest area under the ROC curve (AUC) value (AUC = 0.963), followed by VAI (AUC = 0.937). In female subjects, LAP also had the highest AUC value (AUC = 0.931), followed by VAI (AUC = 0.861). No significant difference was found between the two obesity indicators (P > 0.05).ConclusionThe two obesity indicators were valuable for the screening of MetS in young adults, and LAP was the simpler of the two.

Kishk Sa′eedi as a potential functional food for management of metabolic syndrome: A study of the possible interaction with pomegranate seed oil and/ or gum Arabic

Introduction: In the present research, the health benefits of the traditional Egyptian food called Kishk Sa′eedi (KS) and KS mixed with gum Arabic (GA) or with a mixture of GA and pomegranate seed oil (PSO) were studied in a rat model of metabolic syndrome (MS) induced by feeding high fructose high hydrogenated fat diet (HFFD). Methods: Rats were divided into a normal control group (NC) fed on a balanced diet (Diet 1), a MS control (MSC) receiving HFFD (Diet 2), and three test groups feeding on HFFD containing KS (Diet 3), KS with GA (Diet 4), and KS with GA and PSO (Diet 5), respectively for five weeks. Biochemical and histopathological changes were assessed. Results: Significant increase in blood glucose, plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST), urea, creatinine, uric acid, malondialdehyde (MDA), dyslipidemia and reduction in reduced glutathione (GSH) were demonstrated in MSC compared to NC (P &lt; 0.05). Significant elevation in liver fat, MDA and gene expression of interleukin-6 (IL-6) with significant down-regulation of peroxisome proliferator-activated receptor (PPAR-α) were noticed in MSC compared to NC (P &lt; 0.05). The three test diets improved plasma high-density lipoprotein-cholesterol (HDL-C), uric acid, MDA, liver PPAR-α and IL-6 expression (P &lt; 0.05) compared to MSC without affecting liver lipids. Blood glucose, plasma dyslipidemia, AST, creatinine and urea were improved by diet 3 and diet 5 (P &lt; 0.05). Diet 3 elevated GSH and reduced ALT and MDA (P &lt; 0.05). Histopathological changes induced by HFFD in both liver and kidney showed variable improvement by feeding the tested diets. Conclusion: The tested diets significantly improved MS rat model with superiority to diet 3.